AEON Biopharma (NASDAQ:AEON) vs. Achaogen (OTCMKTS:AKAOQ) Critical Survey

Achaogen (OTCMKTS:AKAOQ) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Analyst Recommendations

This is a summary of current recommendations for Achaogen and AEON Biopharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achaogen	0	0	0	0	0.00
AEON Biopharma	0	1	1	1	3.00

Profitability

This table compares Achaogen and AEON Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Achaogen	N/A	N/A	N/A
AEON Biopharma	N/A	N/A	-994.63%

Earnings and Valuation

This table compares Achaogen and AEON Biopharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achaogen	$8.73 million	0.14	-$186.51 million	N/A	N/A
AEON Biopharma	N/A	N/A	-$36.63 million	$5.04	0.22

AEON Biopharma has lower revenue, but higher earnings than Achaogen.

Institutional and Insider Ownership

22.8% of AEON Biopharma shares are held by institutional investors. 7.8% of Achaogen shares are held by insiders. Comparatively, 0.9% of AEON Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Achaogen has a beta of -0.81, indicating that its share price is 181% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500.

Summary

AEON Biopharma beats Achaogen on 6 of the 9 factors compared between the two stocks.

About Achaogen

Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 29, 2020.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.